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Background: The false negative rate of sentinel lymph node biopsy (SLNB) is 5-10%, and results in improper patient
management. The study was to assess the value of ultrasound-suspicious axillary lymph node biopsy (USALNB) in
patients with early breast cancer, and to compare SLNB combined with USALNB (SLNB + USALNB) with SLNB alone.
Methods: From January 2010 to July 2013, 216 patients with early breast cancer were enrolled consecutively at the
Department of Breast and Thyroid Surgery, Qianfoshan Hospital, Shandong University. All patients underwent wire
localization of the suspicious node by color Doppler ultrasonography, followed by SLNB 2–3 hours later, suspicious
node lymphadenectomy, and level ≥ II axillary dissection (as the gold standard). The predictive values of node status
between SLNB + USALNB and SLNB alone were compared.
Results: The success rate of SLNB was 99.1% (214/216). After axillary dissection, 71 patients were confirmed with
axillary lymph node metastases by pathological examinations. Eight false negatives were observed using SLNB
alone, resulting in sensitivity of 88.7%, specificity of 100%, false negative rate of 11.3%, and false positive rate of 0%
in predicting the axillary node status. SLNB + USALNB resulted in sensitivity of 97.2%, specificity of 100%, false
negative rate of 2.8%, and false positive rate of 0%. The false negative rate of SLNB + USALNB was significantly
different from that of SLNB alone (P = 0.031).
Conclusions: SLNB + USALNB seems to be a low-risk procedure that might be useful in reducing the false negative
rate of SLNB, improving the accuracy of axillary nodes evaluation in early breast cancer.
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The presence or absence of axillary lymph node involve-
ment represents one of the most important prognostic in-
dicators of long-term patient outcome for breast cancer.
In that same regard, accurate axillary staging is extremely
important for guiding the surgical management and for
directing the appropriate selection of adjuvant therapies
for breast cancer. Sentinel lymph node biopsy (SLNB) is* Correspondence: frzmedsci@163.com
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unless otherwise stated.usually performed first because it is less morbid than axil-
lary lymph node dissection (ALND). Therefore, patients
with negative SLNB may avoid unnecessary ALND and its
complications such as upper extremity edema and shoul-
der joint movement disorders [1]. However, the SLNB
technique is associated with a false negative rate of 5 to
10% [2-4]. This high false negative rate is of clinical
concern, and thus new approaches to axillary lymph node
staging are clearly needed to address this issue.
Identification and sampling of suspicious axillary lymph
nodes (SALN) using ultrasound has been proposed in
order to improve axillary staging without the necessity to
perform an ALND. Indeed, a number of recent studiesThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Ultrasound localization of suspicious lymph nodes 2 hours
before SLNB. The red arrow shows the hook wire.
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either using fine needle aspiration (FNA) and/or core nee-
dle biopsy, and showed relatively good predictive value for
axillary status [5-7]. However, most of these studies tested
the use of ultrasound-guided SALN biopsy (USALNB) in-
stead of SLNB, and the use of USALNB alone is associated
with highly variable false positive rates [5] that may impair
its use in a clinical setting. Nevertheless, the use of ultra-
sound to detect the SALN was shown to reduce the reop-
eration rate [8,9].
It is a well-accepted concept that the lymphatic spread
of tumor cells from the primary breast cancer site occurs
through defined regional lymphatic pathways leading to
the axillary region and to other regional lymphatic chains.
Therefore, tumor cells from the primary breast cancer site
will first be recognized within a defined lymph node or
defined group of lymph nodes which we designate as the
sentinel lymph nodes (SLNs) [10]. The ability to recognize
the presence of tumor cell within any given lymph node is
the basis of accurate axillary staging for breast cancer.
While it is intuitive that the early involvement of any given
lymph node by tumor cells may not result in any easily
recognizable alternations in the morphologic characteris-
tics of a lymph node on ultrasound, and that it may
require a greater degree of lymph node involvement to
become sonographically apparent, the use of ultrasound
for axillary staging in breast cancer reasonably well-
established [11]. The use of ultrasound for axillary staging
in breast cancer could be thought of as complementary to
SLNB, as SLNB is not without its own issues as related to
false negativity rates [4].
Therefore, in the present study, we evaluated a new
approach for axillary staging using both SLNB and
USALNB by wire localization. In our study design, we
attempted to evaluate this new approach for predicting
the axillary status by comparing SLNB alone technique
to that of a combined SLNB +USALNB technique, and
utilized concomitant ALND as the gold standard.
Methods
Patients
Between January 2010 and July 2013, 216 consecutive pa-
tients were enrolled at the Department of Breast and Thy-
roid Surgery, Qianfoshan Hospital, Shandong University.
Inclusion criteria were: 1) women with clinical stage I or
II breast cancer according to the AJCC TNM version 6.0
[12]; 2) a single primary breast tumor; 3) no distant metas-
tases; and 4) no history of surgery or radiotherapy on the
same side as the cancer. Exclusion criteria were: 1) neoad-
juvant chemotherapy; 2) neoadjuvant endocrine therapy;
3) local resection surgery performed before axillary sta-
ging; or 4) radiotherapy on the same side as the cancer.
Diagnosis was confirmed by the pathological examination
of percutaneous breast biopsies.The study was approved by the Medical Ethics Com-
mittee of the Qianfoshan Hospital affiliated to Shandong
University (20110133), and written informed consent
was obtained from each participant.
Study design
This was a cohort study aiming to determine the predict-
ive value of the axillary status in early breast cancer using
SLNB alone and SLNB+ USALNB compared with axillary
dissection as the gold standard. All patients underwent, in
order: ultrasound-guided wire localization of the suspi-
cious lymph node, SLNB, USALNB, and ALND.
Lymph node sampling
B-mode ultrasound (Logiq 9, GE Healthcare, Waukesha,
WI, USA) was conducted to determine the axillary lymph
node that was the most likely to arbor a breast cancer me-
tastasis (Figure 1). Because there is no generally accepted
definition of suspicious lymph nodes under ultrasound, a
suspicious lymph node was defined in the present study
as a lymph node >0.5 cm in diameter, a length/width
ratio <1.7, absence of hilum, heterogeneous thickening of
the cortex, and increased peripheral blood flow [13].
Lymph nodes showing these features were present in
almost all patients. Therefore, after a careful examination
of each lymph node, the most suspicious lymph node was
selected for sampling. A hook wire (US Biopsy Breast
Location Needle, Promex Technologies LLC, Franklin, IN,
USA) was used to identify the one or two most suspicious
lymph nodes under ultrasound guidance. If two lymph
nodes were very close, the lymph nodes were identified
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nodes were distant from each other or could not be ob-
served in one ultrasonic range, two hook wires were used.
Two radiologists including one chief and one senior at-
tending doctor were asked to identify the suspicious
lymph nodes. Disagreements were discussed and resolved
by consensus.
SNLB was performed 2–3 hours after ultrasound. A
subcutaneous injection of methylthioninium chloride
(4 ml, 40 mg; Jiangsu Jumpcan Pharmaceutical Group
Co., Ltd., China) was performed at the surface of the
tumor. Methylene blue was used instead of isosulfan or
isotopes because of the limited availability of these prod-
ucts. The skin and subcutaneous tissues were incised
10 min later, and skin flaps were isolated routinely. Adi-
pose connective tissues were incised parallel to the outer
edge of the pectoralis major muscle. After identification of
the blue-stained lymphatic vessels, dissection of the tissues
was performed along the lymphatic vessels to find and re-
sect blue-stained lymph nodes. The resected blue-stained
lymph nodes were labeled as the sentinel lymph nodes for
pathological examinations (Figure 2).
Thereafter, the nodes identified using ultrasound were
removed along the wire. During SLNB, the consistency
between the nodes identified by SLNB and those identi-
fied using ultrasound was examined (Figure 2). The two
methods were considered consistent when the nodes
identified by ultrasounds were found to be stained blue
and inconsistent when nodes other than the ones identi-
fied by ultrasound were stained blue. The ultrasound-
suspicious lymph nodes were all removed with the hook
wire, regardless of SLNB results. Lymph nodes identifiedFigure 2 Identification of suspicious lymph node and SLN during
surgery. The green arrow shows the methylene blue-dyed SLN, while
the yellow arrow indicates the adjacent suspicious lymph node that
was identified by preoperative ultrasound and wire localization. In
this patient, final pathology confirmed that the SLN had no metastasis,
while a metastasis was present in the suspicious lymph node.by hook wires were considered as suspicious lymph
nodes, while blue-stained ones were considered as SLNs.
Suspicious lymph nodes and SLNs were examined
using frozen sections. Axillary lymph nodes may be
divided according to the outer, rear, and inner sides of
the pectoralis minor muscle groups, according to the
conventional surgical grouping criteria of axillary lymph
nodes. In all cases, a standard ALND of levels I/II or
levels I/II/III was performed regardless of the results of
SLNB and/or USALNB. Breast-conserving surgery or
mastectomy was then performed, based on the decision
reached by the patient following discussion with the sur-
geon. Adjuvant chemotherapy, radiotherapy, hormonal
therapy, and biological therapy were administered post-
operation according to each cancer, in a standard manner.
All lymph nodes sampled were subjected to standard
pathological examination, including hematoxylin & eosin
(H&E) staining, and estrogen receptor, progesterone
receptor and HER2 immunohistochemistry. Cytokeratins
were not evaluated in the lymph nodes due to the
limited amount of available tissues. H&E staining were
considered as the gold standard to assess sensitivity and
false negative rate.
Pathologists were blind regarding the origin of the
lymph nodes. All researchers were blind to the patho-
logical results.
Follow-up
All patients were followed up after treatments were com-
pleted. Follow-up was performed every 6 months by plain
X-ray of the chest, bone scanning, ultrasound examination
of the liver, thoracic wall and breasts, and axillary ultra-
sound examination, according to the NCCN guidelines.
Statistical analysis
Data are presented as mean ± standard deviation (SD), ab-
solute numbers and percentages. Variables within the con-
tingency tables were analyzed using the χ2 or the Fisher
exact test, as appropriate. SPSS 16.0 (SPSS Inc., Chicago,
IL, USA) was used for statistical analysis. P-values <0.05
were considered statistically significant.
Results
Patients’ characteristics
Age ranged from 26 to 68 years old. All patients were
without clinically palpable nodes before surgery. There
were 76 patients with clinical stage I breast cancer and
140 patients with clinical stage II breast cancer (according
to the AJCC TNM, 6th edition). Tumor was found in the
upper outer quadrant in 96 cases, in the lower outer quad-
rant in 54 cases, in the upper inner quadrant in 12 cases,
in the lower inner quadrant in 10 cases, and in the central
quadrant in 44 cases. Of these cases, 196 underwent
modified radical mastectomy, and 20 underwent breast-
Table 2 Presence of node metastases and pathologic
features of the primary tumors
Characteristic Value
N of nodes excised,
mean (range)
20.3 (12–36)
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carcinomas (85.2%). Tumor grade was I in 10.2% of cases,
II in 83.3% and III in 6.5%. Tumors were hormone
receptor-positive in 66.2% of cases, HER2-positive in
19.4%, and 68.1% showed a Ki-67 index >14% (Table 1).N of SLN excised,
mean (range)
2.3 (1–5) (1 node in 54 cases, 2 nodes in
78 cases, 3 nodes in 60 cases, >3 nodes
in 22 cases)
N of suspicious lymph node
excised, mean (range)
1.3 (1–2) (1 node in 150 cases,
2 nodes in 64 cases)
Nodal metastases
No metastasis 145 (67.1%)
Metastases 71 (32.9%)
SLN: sentinel lymph node.Lymph node status
SLNB using the methylene blue dye technique was suc-
cessful in 99.1% of patients. A mean of 2.3 (range: 1–5)
SLNs were excised, with 1 SLN in 54 patients, 2 SLNs in
78 patients, 3 SLNs in 60 patients, and >3 SLNs in 22 pa-
tients. A mean of 1.3 (range 1–2) SALN were identified by
ultrasound and excised, including 1 SALN in 150 patients
and 2 SALNs in 64 patients (Table 2). A mean of 20.3
(range: 12–36) lymph nodes were excised by ALND.
Postoperative pathological examination of axillary
lymph nodes obtained by ALND showed that 143 cases
were negative, and that 71 cases were positive. Among
these 71 positive cases, SLNB alone indicated that 63 were
node-positive. Ultrasound indicated suspicious lymphTable 1 Patients' demographic and clinical characteristics
Characteristics Value
Age
Mean ± SD (years) 52.1 ± 10.3
Range 22-66
≤50 years 99 (45.8%)





















AJCC: American joint committee on cancer.nodes in 35 patients. Therefore, using the combination of
SLNB and USALNB, 69 cases were node-positive.
Sentinel lymph node biopsy alone
Table 3 shows the predictive value of SLNB alone. Using
ALND results as the gold standard, sensitivity was 88.7%,
specificity was 100%, false negative rate was 11.3% and
false positive rate was 0%.
Sentinel lymph node biopsy and ultrasound-suspicious
lymph node biopsy
Table 4 shows the predictive value of SLNB + USALNB.
Using ALND results as the gold standard, sensitivity was
97.2%, specificity was 100%, false negative rate was 2.8%
and false positive rate was 0%.
Table 5 shows the predictive value of SLNB +USALNB.
Using SLNB results as the gold standard, compared with
SLNB alone, SLNB +USALNB had a better false negative
rate (2.8% vs. 11.3%, P = 0.031).
Follow-up data
During follow-up period (mean of 19 ± 4.5 months), only
two patients were noted to develop distant metastatic
disease.
The first patient was a 65-year-old female patient with
grade II invasive ductal carcinoma (left breast, 4 cm). She
underwent a level II ALND, and all sampled lymph nodes
were negative. Tumor immunohistochemistry revealed a
triple-negative breast cancer, P53-positive, and the Ki-67
index was <40%. She received four cycles of docetaxel and
cyclophosphamide. Pulmonary and bone metastases were
found one year after surgery.
The second patient was a 31-year-old female patient
with grade II invasive ductal carcinoma (left breast,
1.7 cm). She underwent level II ALND and all sampled
lymph nodes were negative. She received epirubicine,
5-fluorouracil and cyclophosphamide for 6 cycles,
followed by 2 months of oral toremifene. The patient
Table 3 Comparison of the pathological results of SLNB
between methylene blue and H&E staining
SLNB ALNB Total
+ -
+ 63 0 63
- 8 143 151
Total 71 143 214
Sensitivity = 63/71 = 88.7%.
Specificity = 143/143 = 100%.
False negative rate = 8/71 = 11.3%.
False positive rate = 0/143 = 0%.
SLNB: sentinel lymph node biopsy.
Table 5 Comparison of pathological results between
SLNB and combined use of SLNB, suspicious lymph
node biopsy
SLNB SLNB + USALNB Total
+ -
+ 63 0 63
- 6 145 151
Total 69 145 214
SLNB: sentinel lymph node biopsy.
Compared with SLNB, SLNB + USALNB had a better false negative rate
(2.8% vs. 11.3%, P = 0.031).
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vertebral metastases were found two years after surgery.
Discussion
Axillary lymph node status is one of the most important
prognostic factors in patients with breast cancer, and is
used for the selection of the appropriate adjuvant ther-
apy. ALND was previously the standard management of
the axilla in breast cancer, but ALND failed to add bene-
fits to node-negative patients. In addition, ALND results
in certain complications, such as upper limb edema and
shoulder joint movement disorders. Recent studies using
large randomized samples, such as the ALMANAC [14]
and NSABP B-32 [15] trials, have shown that the false
negative rate of the axillary lymph node status predicted
by SLNB was 5-10%. False negatives affect the staging
and proper choice of treatment.
Therefore, the aim of the present study was to assess
the value of USALNB in patients with early breast can-
cer, and to compare SLNB + USALNB with SLNB alone.
Results showed that SLNB +USALNB resulted in a sig-
nificantly better false negative rate (2.8%) compared with
SLNB alone (11.3%).
Preoperative ultrasound can be used to make a prelim-
inary assessment of the status of the axillary lymph
nodes [16,17]. Ultrasound is particularly important for
patients with smaller non-palpable lymph nodes. Meta-
static lymph nodes present some typical characteristics,Table 4 Comparison, pathological results between
methylene blue staining of SLNB + suspicious lymph
node biopsy, pathological results
SLNB + USALNB ALNB Total
+ -
+ 69 0 69
- 2 143 145
Total 71 143 214
Sensitivity = 69/71 = 97.2%.
Specificity = 143/143 = 100%.
False negative rate = 2/71 = 2.8%.
False positive rate = 0/143 = 0%.
SLNB: sentinel lymph node biopsy.such as enlargement, signal heterogeneity, and disorderly
flow distribution [13]. However, in clinical practice, some
metastatic lymph nodes show no typical manifestation.
Based on their location and imaging findings, the most
likely metastatic lymph nodes were regarded as the suspi-
cious lymph nodes. Previous studies have shown that an
overlap exists between the SLNs and the suspicious lymph
nodes [18,19]. In the present study, some suspicious
lymph nodes (82/214, 38.3%) were indeed SLNs. Thus,
SLNB was easier to conduct, and the possibility of missing
a positive lymph node was reduced.
The factors contributing the occurrence of false nega-
tive results during SLNB can be multifactorial, including
variability in lymphatic drainage pathway, variability in
SLNB techniques utilized, varying levels of surgeon ex-
perience, and patient selection issues. All current meth-
odologies for SLNB, including the blue dye technique
alone, the isotope technique alone, or the combined blue
dye/isotope technique, rely on the lymphatic drainage
pathways for successful outcome. Lymphatic drainage
pathways depends on the integrity and physiology of the
lymphatic channels and the corresponding lymph nodes
[20]. Once the integrity of these structures is disrupted
or altered, the lymphatic flow direction may also be dis-
rupted or altered [21], which may in turn lead to false
negative results. Investigations have suggested that the
lymphatic drainage pathways for the nipple/areola com-
plex region of the breast and other areas of the breast can
geographically differ [22]. This difference may also con-
tribute to variability in the degree of false negative results
reported by various investigators [4,22-24]. Thus, the use
of a combined approach of SLNB with ultrasound-guided
axillary sampling of suspicious axillary lymph nodes could
represent an advantageous alternative for the assessment
of the axillary lymph node status. Previous studies on the
use of four to five lymph node samplings from the axilla
[25,26] showed a false negative rate similar to that of
SLNB, despite ultrasound, magnetic resonance imaging,
positron emission tomography and computed tomog-
raphy. Furthermore, some studies showed that four lymph
nodes may be dissected as a supplement to SLNB to
reduce the false negative rate [27]. However, the results
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studies recently addressed ultrasound-guided axillary
sampling as an alternate/additional staging procedure to
improve the accuracy of SLNB [29,30]. However, the use
of ultrasound alone to guide the biopsy of axillary lymph
nodes (performed using either FNA or core needle biopsy)
resulted in highly variable false negative rates [5], thus
compromising its use in the clinical setting. Compared
with the false negative rate of 11.3% using SLNB alone,
the present study showed that ultrasound-guided axillary
sampling of suspicious axillary lymph nodes along with
SLNB yielded a significantly lower false negative rate of
2.8%. Thus, ultrasound-guided axillary sampling of suspi-
cious axillary lymph nodes improved the accuracy of the
staging of the axillary lymph nodes. This suggests that the
addition of ultrasound-guided axillary sampling of suspi-
cious axillary lymph nodes to axillary staging can effect-
ively complement the standard utilization of SLNB alone,
and for which the combined use of these two methodolo-
gies in axillary staging could have more far-reaching im-
pact on determining more appropriate adjuvant therapies.
However, the lack of a consensus on the standardization
of quantitative indicators for defining suspicious axillary
lymph nodes on ultrasound evaluation remains a signifi-
cant issue, and contributes to the continued inability to
effectively apply this methodology to clinical practice.
In many countries, SLNB is performed using an isotope
(such as 99 m-Tc-colloid) in combination with a blue dye
(such as methylene blue or isosulfan blue). However, in
China, secondary to isotope shortage and governmental
regulations, blue dye (i.e., methylene blue) is generally
used alone for axillary staging for breast cancer, as in
accordance with the breast cancer treatment guidelines
and norms (2011 edition) from the Chinese Anti-Cancer
Association. These established guidelines state that
methylene blue may be used alone for SNLB, and that the
results are reliable. Nevertheless, if isotope, such as 99 m-
Tc-colloid, was more readily available to medical centers
throughout China, then our current analysis would have
been able to undertake a comparison of SLNB alone (by
the methylene blue and isotope technique) versus SLNB
(by the methylene blue and isotope technique) plus
USALNB, which would be more applicable to the
approach for axillary staging which is practiced inter-
nationally in other developed countries outside of China.
Nevertheless, previous studies have demonstrated that the
results from the use of a blue dye alone were comparable
to the combined use of blue dye and isotope [31,32].
Furthermore, research has shown that the results from the
use of methylene blue combined with an isotope were
comparable to those obtained using isosulfan blue com-
bined with an isotope [33]. Therefore, it is our belief that
results of our present study regarding the role of adding
USALNB to SLNB by blue dye alone (and withoutisotope) appear to be generalizable to the approach for
axillary staging which is practiced internationally in other
developed countries outside of China. However, realistic-
ally, prospective randomized clinical trials in larger patient
populations will be necessary to confirm this.
The present study is not without limitations. First, the
sample size was not very large, and the study was not
randomized. In addition, the follow-up was short, and
longer follow-up is necessary to correctly assess recur-
rences. Multicenter randomized studies should be
performed to correctly assess the predictive value of
SLNB +USALNB.Conclusion
The present study showed that USALNB+ SLNB was bet-
ter than SLNB alone. Moreover, this method was simple
to use, and has potential clinical applications. However,
the quantitative indicators of suspicious axillary lymph
nodes need further investigation.
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